Oral Liraglutide Nanoparticles: Chitosan-Coated Delivery System Provides Sustained Blood Sugar Control
Zein/Eudragit-chitosan nanoparticles delivered liraglutide orally with sustained release and glycemic control, potentially replacing daily injections with an oral pill.
Quick Facts
What This Study Found
Zein/Eudragit-chitosan nanoparticles protected liraglutide from gastric degradation, provided sustained oral delivery, and achieved effective glycemic control in animal models.
Key Numbers
Oral nanoparticle formulation achieved comparable pharmacokinetic and glycemic outcomes to subcutaneous injection in diabetic rats.
How They Did This
Formulated liraglutide-loaded zein/Eudragit nanoparticles coated with chitosan. Characterized particle size, encapsulation, release kinetics, acid stability, and in vivo glycemic control.
Why This Research Matters
Liraglutide injection is a barrier to patient adherence. An oral nanoparticle formulation could make this effective GLP-1 drug as easy as taking a pill, dramatically expanding its use.
The Bigger Picture
Oral delivery of peptide drugs is one of pharmaceutical science's biggest challenges. While oral semaglutide (Rybelsus) uses a different approach (SNAC enhancer), nanoparticle-based delivery could offer sustained release profiles that are difficult to achieve with enhancer technology, potentially enabling once-daily or even less frequent oral GLP-1 therapy.
What This Study Doesn't Tell Us
Animal study — human GI conditions and absorption may differ. Bioavailability compared to injection needs quantification. Manufacturing scalability and cost of nanoparticles need assessment.
Questions This Raises
- ?How does oral nanoparticle liraglutide bioavailability compare to injectable liraglutide?
- ?Could this nanoparticle platform deliver other peptide drugs orally?
- ?What is the manufacturing cost comparison with current injection formulations?
Trust & Context
- Key Stat:
- Oral GLP-1 delivery Zein/Eudragit-chitosan nanoparticles protect liraglutide from stomach acid and deliver it orally with sustained glycemic control
- Evidence Grade:
- Preliminary evidence: formulation study with in vivo glycemic control in animals. Human pharmacokinetics and bioavailability not established.
- Study Age:
- Published in 2024. Advances oral peptide delivery technology for GLP-1 drugs.
- Original Title:
- Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats.
- Published In:
- Pharmaceutics, 16(5) (2024)
- Authors:
- Ziebarth, Jeferson, da Silva, Letícia Marina, Lorenzett, Ariane Krause Padilha, Figueiredo, Ingrid Delbone, Carlstrom, Paulo Fernando, Cardoso, Felipe Nunes, de Freitas, André Luiz Ferreira, Baviera, Amanda Martins, Mainardes, Rubiana Mara
- Database ID:
- RPEP-09697
Evidence Hierarchy
Frequently Asked Questions
Could liraglutide become an oral pill?
This study shows that nanoparticle technology can protect liraglutide from stomach acid and deliver it through the intestines with sustained release. While not yet available as a product, this technology could eventually enable oral liraglutide pills.
How do the nanoparticles protect liraglutide?
The nanoparticles use three layers of protection: zein (corn protein) forms the core, Eudragit provides acid resistance in the stomach, and chitosan coating promotes adhesion to intestinal walls for absorption. Together, they shield liraglutide until it reaches the right part of the gut.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09697APA
Ziebarth, Jeferson; da Silva, Letícia Marina; Lorenzett, Ariane Krause Padilha; Figueiredo, Ingrid Delbone; Carlstrom, Paulo Fernando; Cardoso, Felipe Nunes; de Freitas, André Luiz Ferreira; Baviera, Amanda Martins; Mainardes, Rubiana Mara. (2024). Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats.. Pharmaceutics, 16(5). https://doi.org/10.3390/pharmaceutics16050634
MLA
Ziebarth, Jeferson, et al. "Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats.." Pharmaceutics, 2024. https://doi.org/10.3390/pharmaceutics16050634
RethinkPeptides
RethinkPeptides Research Database. "Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan N..." RPEP-09697. Retrieved from https://rethinkpeptides.com/research/ziebarth-2024-oral-delivery-of-liraglutideloaded
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.